Plain-English translation of NCT05334615 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Researchers at the University of Iowa are studying why COVID-19 increases the risk of dangerous blood clots in hospitalized patients. This study will collect blood samples from people admitted to the hospital with COVID-19, people who happen to have COVID-19 but were admitted for other reasons, and people with the flu (as a comparison group). By examining these samples, the team hopes to understand exactly how the coronavirus triggers the body's blood-clotting system to go into overdrive.
Some COVID-19 patients develop severe blood clotting problems that can lead to organ failure and death, but doctors don't yet fully understand the mechanism. This study aims to identify which blood cells and processes are responsible so that better treatments can be developed.
You likely qualify if…
You likely don't qualify if…
If you qualify, you will be asked to donate blood samples when you enter the hospital and then weekly during your stay (for up to 30 days). The researchers will analyze your blood in the lab to study how your body's clotting system responds to infection. There are no experimental medications or procedures — you simply provide blood samples while receiving your normal hospital care.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
United States
Enrollment target
~180 participants
Started
January 2022
Primary completion
December 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years – 99 Years
Last updated on clinicaltrials.gov in April 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Steven Lentz, MD, PhD
University of Iowa
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.